Marfloxin 20 mg/ml solution for injection for calves, pigs, dogs and cats

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

Marbofloxacin

Commercializzato da:

Krka, d.d., Novo mesto

Codice ATC:

QJ01MA93

INN (Nome Internazionale):

Marbofloxacin

Dosaggio:

20 milligram(s)/millilitre

Forma farmaceutica:

Solution for injection

Tipo di ricetta:

POM: Prescription Only Medicine as defined in relevant national legislation

Gruppo terapeutico:

Cats, Cattle, Dogs, Pigs

Area terapeutica:

marbofloxacin

Indicazioni terapeutiche:

Antibacterial

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2011-08-26

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marfloxin 20 mg/ml solution for injection for calves, pigs, dogs and
cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Marbofloxacin
20 mg
EXCIPIENTS:
Metacresol
2 mg
Disodium edetate
0.10 mg
Monothioglycerol
0.50 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, greenish yellow to brownish yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Calves (pre-ruminant and ruminant), pigs, dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections due to marbofloxacin susceptible strains of
bacteria.
In Calves
Treatment of respiratory infections caused by_ Histophilus somni,
Mannheimia haemolytica_ and_ Pasteurella multocida._
In Pigs
Treatment of respiratory infections.
Treatment of Metritis Mastitis Agalactia (MMA) syndrome.
In Dogs
Treatment of infected wounds and abscesses.
Treatment of lower urinary tract infections due to_ Escherichia coli_
and_ Proteus mirabilis._
Prevention of surgical infections due to_ Staphylococcus intermedius,
Escherichia coli_ and_ Pseudomonas aeruginosa_.
In Cats
Treatment of infected wounds and abscesses.
Prevention of surgical infections due to_ Staphylococcus intermedius,
Escherichia coli_ and_ Pseudomonas aeruginosa_.
4.3 CONTRAINDICATIONS
Do not use in cases where the pathogen involved is resistant to other
fluoroquinolones (cross resistance).
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a